Roche Holding expects the obesity market to split into segments as weight-loss drugs reach the wider public, opening the door for new players to take on Eli Lilly and Novo Nordisk.
“We are literally scratching the surface, and underneath that is a whole world of unmet needs that patients are desperately waiting for,” said Manu Chakravarthy, Roche’s global head of cardiovascular, renal and metabolism product development and one of the executives in charge of leading the pharmaceutical giant’s bid to re-enter the obesity market.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8